A new DNA-based immune treatment for recurring HPV-related airway growths has received accelerated FDA approval for adults, according to this announcement. Called Voceryq, it aims to help the immune system attack infected cells rather than relying only on repeated surgery to remove growths. The treatment delivers instructions for selected HPV proteins and an immune-boosting protein through a muscle injection supported by brief electrical pulses. The FDA cites a study involving 32 adults and evidence of reduced surgical frequency. However, the supplied article ends before presenting complete results and does not include detailed safety findings. For adults with this rare condition, the treatment could offer another option to discuss with specialists. Additional studies must confirm its clinical benefit; it is not an established cure or a general HPV treatment.
